Search

Your search keyword '"Del Mastro L"' showing total 865 results
Start Over Author "Del Mastro L"
865 results on '"Del Mastro L"'

2. Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial

Author

Poggio, F., Blondeaux, E., Tagliamento, M., Perachino, M., Nardin, S., Conte, B., Giuliano, M., Arpino, G., De Laurentiis, M., Gravina, A., Bisagni, G., Rimanti, A., Turletti, A., Nisticò, C., Magnolfi, E., Gasparro, S., Fabi, A., Garrone, O., Alicicco, M.G., Urracci, Y., Poletti, P., Correale, P., Molinelli, C., Fozza, A., Puglisi, F., Colantuoni, G., Fregatti, P., Boni, L., Lambertini, M., and Del Mastro, L.

Published
2024
Full Text
View/download PDF

3. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Author

Loibl, S., André, F., Bachelot, T., Barrios, C.H., Bergh, J., Burstein, H.J., Cardoso, M.J., Carey, L.A., Dawood, S., Del Mastro, L., Denkert, C., Fallenberg, E.M., Francis, P.A., Gamal-Eldin, H., Gelmon, K., Geyer, C.E., Gnant, M., Guarneri, V., Gupta, S., Kim, S.B., Krug, D., Martin, M., Meattini, I., Morrow, M., Janni, W., Paluch-Shimon, S., Partridge, A., Poortmans, P., Pusztai, L., Regan, M.M., Sparano, J., Spanic, T., Swain, S., Tjulandin, S., Toi, M., Trapani, D., Tutt, A., Xu, B., Curigliano, G., and Harbeck, N.

Published
2024
Full Text
View/download PDF

4. Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients

Author

Arenare, L., Porta, C., Barberio, D., Terzolo, S., Zagonel, V., Pisconti, S., Del Mastro, L., Pinto, C., Bilancia, D., Cinieri, S., Rizzo, M., Migliaccio, G., Montesarchio, V., Del Campo, L., De Lorenzo, F., Iannelli, E., Traclò, F., Gitto, L., Vaccaro, M.C., Frontini, L., Giannarelli, D., Bryce, J., Piccirillo, M.C., Jommi, C., Efficace, F., Riva, S., Di Maio, M., Gallo, C., and Perrone, F.

Published
2023
Full Text
View/download PDF

6. Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis

Author

Arecco, L., Blondeaux, E., Bruzzone, M., Latocca, M.M., Mariamidze, E., Begijanashvili, S., Sokolovic, E., Gentile, G., Scavone, G., Ottonello, S., Boutros, A., Vaz-Luis, I., Saura, C., Anderson, R.A., Demeestere, I., Azim, H.A., Jr, de Azambuja, E., Peccatori, F.A., Del Mastro, L., Partridge, A.H., and Lambertini, M.

Published
2023
Full Text
View/download PDF

8. Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study

Author

Lambertini, M, Blondeaux, E, Agostinetto, E, Hamy, A, Kim, H, Di Meglio, A, Molho, R, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Ignatiadis, M, Moore, H, Phillips, K, Toss, A, Rousset-Jablonski, C, Peccatori, F, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Ruddy, K, Dieci, M, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Del Mastro, L, Puglisi, F, Estevez-Diz, M, Rodriguez-Wallberg, K, Mrinakova, B, Meister, S, Livraghi, L, Clatot, F, Yerushalmi, R, De Angelis, C, Sanchez-Bayona, R, Meattini, I, Cichowska-Cwalinska, N, Berliere, M, Salama, M, De Giorgi, U, Sonnenblick, A, Chiodi, C, Lee, Y, Maria, C, Azim, H, Boni, L, Partridge, A, Lambertini M., Blondeaux E., Agostinetto E., Hamy A. -S., Kim H. J., Di Meglio A., Molho R. B., Hilbers F., Pogoda K., Carrasco E., Punie K., Bajpai J., Ignatiadis M., Moore H. C. F., Phillips K. -A., Toss A., Rousset-Jablonski C., Peccatori F. A., Renaud T., Ferrari A., Paluch-Shimon S., Fruscio R., Cui W., Wong S. M., Vernieri C., Ruddy K. J., Dieci M. V., Matikas A., Rozenblit M., Villarreal-Garza C., De Marchis L., Del Mastro L., Puglisi F., Estevez-Diz M. D. P., Rodriguez-Wallberg K. A., Mrinakova B., Meister S., Livraghi L., Clatot F., Yerushalmi R., De Angelis C., Sanchez-Bayona R., Meattini I., Cichowska-Cwalinska N., Berliere M., Salama M., De Giorgi U., Sonnenblick A., Chiodi C., Lee Y. -J., Maria C., Azim H. A., Boni L., Partridge A. H., Lambertini, M, Blondeaux, E, Agostinetto, E, Hamy, A, Kim, H, Di Meglio, A, Molho, R, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Ignatiadis, M, Moore, H, Phillips, K, Toss, A, Rousset-Jablonski, C, Peccatori, F, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Ruddy, K, Dieci, M, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Del Mastro, L, Puglisi, F, Estevez-Diz, M, Rodriguez-Wallberg, K, Mrinakova, B, Meister, S, Livraghi, L, Clatot, F, Yerushalmi, R, De Angelis, C, Sanchez-Bayona, R, Meattini, I, Cichowska-Cwalinska, N, Berliere, M, Salama, M, De Giorgi, U, Sonnenblick, A, Chiodi, C, Lee, Y, Maria, C, Azim, H, Boni, L, Partridge, A, Lambertini M., Blondeaux E., Agostinetto E., Hamy A. -S., Kim H. J., Di Meglio A., Molho R. B., Hilbers F., Pogoda K., Carrasco E., Punie K., Bajpai J., Ignatiadis M., Moore H. C. F., Phillips K. -A., Toss A., Rousset-Jablonski C., Peccatori F. A., Renaud T., Ferrari A., Paluch-Shimon S., Fruscio R., Cui W., Wong S. M., Vernieri C., Ruddy K. J., Dieci M. V., Matikas A., Rozenblit M., Villarreal-Garza C., De Marchis L., Del Mastro L., Puglisi F., Estevez-Diz M. D. P., Rodriguez-Wallberg K. A., Mrinakova B., Meister S., Livraghi L., Clatot F., Yerushalmi R., De Angelis C., Sanchez-Bayona R., Meattini I., Cichowska-Cwalinska N., Berliere M., Salama M., De Giorgi U., Sonnenblick A., Chiodi C., Lee Y. -J., Maria C., Azim H. A., Boni L., and Partridge A. H.

Abstract

(Abstracted from JAMA 2024;331(1):49-59 Individuals who are diagnosed with breast cancer at a young age are often carriers of a pathogenic variant in the BRCA1 or BRCA2 genes, and many young women in this situation are interested in preserving future fertility, if possible. Reproductive counseling in this situation can be complex due to the risk of passing on the variant, as well as the implications on their own fertility, as the mutation can impact ovarian reserve, fertility potential, and other factors.

Published
2024

9. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature

Author

Boutros, A., Bottini, A., Rossi, G., Tanda, E.T., Spagnolo, F., Barletta, G., Croce, E., Fava, P., Parisi, A., De Rosa, F., Palla, M., Marconcini, R., Ferrari, M., Grandis, M., Spallarossa, P., Sarocchi, M., Arboscello, E., Del Mastro, L., Lambertini, M., Pronzato, P., and Genova, C.

Published
2023
Full Text
View/download PDF

10. Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group

Author

Balic, Marija, Heibl, Sonja, Zabernigg, August Felix, Egle, Daniel, Sandholzer, Margit, Roitner, Florian, Andel, Johannes, Pichler, Petra, Hager, Christopher, Knauer, Michael, Hubalek, Michael, Bighin, Claudia, De Laurentiis, Michelino, De Placido, Sabino, Puglisi, Fabio, Boni, Luca, de Gregorio, Amelie, Degenhardt, Tom, Formisano, Luigi, Beelen, Karin, Robinson, Timothy, Fitzpatrick, Amanda, Dieras, Veronique, Muller, Volkmar, Gennari, Alessandra, Linn, Sabine, Braga, Sofia, Cortes, Javier, Palmieri, Carlo, Gampenrieder, S.P., Dezentjé, V., Lambertini, M., de Nonneville, A., Marhold, M., Le Du, F., Cortés Salgado, A., Alpuim Costa, D., Vaz Batista, M., Chic Ruché, N., Tinchon, C., Petzer, A., Blondeaux, E., Del Mastro, L., Targato, G., Bertucci, F., Gonçalves, A., Viret, F., Bartsch, R., Mannsbart, C., Deleuze, A., Robert, L., Saavedra Serrano, C., Gion Cortés, M., Sampaio-Alves, M., Vitorino, M., Pecen, L., Singer, C., Harbeck, N., Rinnerthaler, G., and Greil, R.

Published
2023
Full Text
View/download PDF

12. Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force

Author

Razis, E., Escudero, M.J., Palmieri, C., Mueller, V., Bartsch, R., Rossi, G., Gampenrieder, S.P., Kolberg, H.C., Zdenkowski, N., Pavic, M., Connolly, R.M., Rosset, L., Arcuri, J., Tesch, H., Vallejos, C., Retamales, J., Musolino, A., Del Mastro, L., Christodoulou, C., Aebi, S., Paluch-Shimon, S., Gupta, S., Ohno, S., Macpherson, I., Ekholm, M., Zaman, K., Vidal, M., Chakiba, C., Fumagalli, D., Thulin, A., Witzel, I., Kotecki, N., Gil-Gil, M., and Linderholm, B.

Published
2022
Full Text
View/download PDF

13. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

Author

Zhang, Q., Xu, B., Shao, Z., Wang, X., Geng, C., Yan, X., Tong, Z., Shen, K., Yin, Y., Sun, T., Yang, J., Feng, J., Yan, M., Wang, Y., Liu, Q., Zhang, S., De Laurentiis, M., Santoro, A., Guarneri, V., Colleoni, M., Natoli, C., Cortesi, L., Placido, S., Gianni, L., Ferrau, F., Livi, L., Zambelli, A., Del Mastro, L., Tonini, G., Montemurro, F., Bianchi, G., Pedersini, R., Prete, S., Allegrini, G., Naso, G., Vici, P., Loirat, D., Mailliez, A., Priou, F., Tredan, O., Dalenc, F., Perrin, C., Gligorov, J., Timar David, M., Dohollou, N., Teixeira, L., Brocard, F., Arnaud, A., Delaloge, S., Spano, J.-P., Mansi, L., Andrade, L., Damian, F., Pedrini, J., Aleixo, S., Hegg, R., Junior, R., Reinisch, M., Schmidt, M., Wenzel, C., Grischke, E.-M., Schneeweiss, A., Just, M., Harbeck, N., Schumacher, C., Peters, U., Fischer, D., Forstbauer, H., Liersch, R., Warner, E., Bouganim, N., Doyle, C., Price Hiller, J., Vandenberg, T., Pavic, M., Robinson, A., Roldan Urgoiti, G., Califaretti, N., Alacacioglu, A., Gumus, M., Yalcin, B., Cicin, I., Kose, F., Uygun, K., Kaplan, M., Cubukcu, E., Wardley, A., Harries, M., Miles, D., Doval, D., Gupta, S., Mohapatra, P., Chatterjee, S., Ghadyalpatil, N., Singhal, M., Nag, S., Agarwal, A., Wolf, I., Gal Yam, E., Yerushalmi, R., Peretz, T., Fried, G., Ben Baruch, N., Katz, D., Hamilton, E., Kayali, F., Brufsky, A., Telli, M., Wright, G., Oyola, R., Rakowski, T., Graff, S., Tjulandin, S., Semiglazov, V., Aparicio, A., Ruiz Borrego, M., Merino, L., Guerra Martinez, J., Lopez, E., Yamashita, T., Ohtani, S., Inoue, K., Ito, Y., Niikura, N., Nakayama, T., Sagara, Y., Yanagita, Y., Kamada, Y., Kaneko, K., Kaen, D., Nervo, A., Eniu, A., Schenker, M., Priester, P., Melichar, B., Zimovjanova, M., Sormova, P., Sufliarsky, J., Kakalejcik, M., Belbaraka, R., Errihani, H., Le Than, D., Pham, D., Aravantinos, G., Papadimitriou, C., Koumakis, G., Papandreou, C., Podolski, P., Tabane, K., André, F., Cameron, D., Barrios, C., Patel, S., Patre, M., Morales, L., Patel, S.L., Kaul, M., Barata, T., and O’Shaughnessy, J.

Published
2021
Full Text
View/download PDF

15. T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study

Author

Schettini, F., Conte, B., Buono, G., De Placido, P., Parola, S., Griguolo, G., Fabi, A., Bighin, C., Riccardi, F., Cianniello, D., De Laurentiis, M., Puglisi, F., Pelizzari, G., Bonotto, M., Russo, S., Frassoldati, A., Pazzola, A., Montemurro, F., Lambertini, M., Guarneri, V., Cognetti, F., Locci, M., Generali, D., Conte, P., De Placido, S., Giuliano, M., Arpino, G., and Del Mastro, L.

Published
2021
Full Text
View/download PDF

16. Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)

Author

De Angelis, C., Bruzzese, D., Bernardo, A., Baldini, E., Leo, L., Fabi, A., Gamucci, T., De Placido, P., Poggio, F., Russo, S., Forestieri, V., Lauria, R., De Santo, I., Michelotti, A., Del Mastro, L., De Laurentiis, M., Giuliano, M., De Placido, S., and Arpino, G.

Published
2021
Full Text
View/download PDF

17. Pregnancy After Breast Cancer in Young BRCA Carriers

Author

Lambertini, M, Blondeaux, E, Agostinetto, E, Hamy, A-S, Kim, HJ, Di Meglio, A, Molho, RB, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Ignatiadis, M, Moore, HCF, Phillips, K-A, Toss, A, Rousset-Jablonski, C, Peccatori, FA, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, SM, Vernieri, C, Ruddy, KJ, Dieci, MV, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Del Mastro, L, Puglisi, F, Estevez-Diz, MDP, Rodriguez-Wallberg, KA, Mrinakova, B, Meister, S, Livraghi, L, Clatot, F, Yerushalmi, R, De Angelis, C, Sanchez-Bayona, R, Meattini, I, Cichowska-Cwalinska, N, Berliere, M, Salama, M, De Giorgi, U, Sonnenblick, A, Chiodi, C, Lee, Y-J, Maria, C, Azim, HA, Boni, L, Partridge, AH, Lambertini, M, Blondeaux, E, Agostinetto, E, Hamy, A-S, Kim, HJ, Di Meglio, A, Molho, RB, Hilbers, F, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Ignatiadis, M, Moore, HCF, Phillips, K-A, Toss, A, Rousset-Jablonski, C, Peccatori, FA, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, SM, Vernieri, C, Ruddy, KJ, Dieci, MV, Matikas, A, Rozenblit, M, Villarreal-Garza, C, De Marchis, L, Del Mastro, L, Puglisi, F, Estevez-Diz, MDP, Rodriguez-Wallberg, KA, Mrinakova, B, Meister, S, Livraghi, L, Clatot, F, Yerushalmi, R, De Angelis, C, Sanchez-Bayona, R, Meattini, I, Cichowska-Cwalinska, N, Berliere, M, Salama, M, De Giorgi, U, Sonnenblick, A, Chiodi, C, Lee, Y-J, Maria, C, Azim, HA, Boni, L, and Partridge, AH

Abstract

IMPORTANCE: Young women with breast cancer who have germline pathogenic variants in BRCA1 or BRCA2 face unique challenges regarding fertility. Previous studies demonstrating the feasibility and safety of pregnancy in breast cancer survivors included limited data regarding BRCA carriers. OBJECTIVE: To investigate cumulative incidence of pregnancy and disease-free survival in young women who are BRCA carriers. DESIGN, SETTING, AND PARTICIPANTS: International, multicenter, hospital-based, retrospective cohort study conducted at 78 participating centers worldwide. The study included female participants diagnosed with invasive breast cancer at age 40 years or younger between January 2000 and December 2020 carrying germline pathogenic variants in BRCA1 and/or BRCA2. Last delivery was October 7, 2022; last follow-up was February 20, 2023. EXPOSURE: Pregnancy after breast cancer. MAIN OUTCOMES AND MEASURES: Primary end points were cumulative incidence of pregnancy after breast cancer and disease-free survival. Secondary end points were breast cancer-specific survival, overall survival, pregnancy, and fetal and obstetric outcomes. RESULTS: Of 4732 BRCA carriers included, 659 had at least 1 pregnancy after breast cancer and 4073 did not. Median age at diagnosis in the overall cohort was 35 years (IQR, 31-38 years). Cumulative incidence of pregnancy at 10 years was 22% (95% CI, 21%-24%), with a median time from breast cancer diagnosis to conception of 3.5 years (IQR, 2.2-5.3 years). Among the 659 patients who had a pregnancy, 45 (6.9%) and 63 (9.7%) had an induced abortion or a miscarriage, respectively. Of the 517 patients (79.7%) with a completed pregnancy, 406 (91.0%) delivered at term (≥37 weeks) and 54 (10.4%) had twins. Among the 470 infants born with known information on pregnancy complications, 4 (0.9%) had documented congenital anomalies. Median follow-up was 7.8 years (IQR, 4.5-12.6 years). No significant difference in disease-free survival was observed between patie

Published
2024

18. Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial

Author

Malorni, L, Bianchini, G, Caputo, R, Zambelli, A, Puglisi, F, Bianchi, G, Del Mastro, L, Paris, I, Montemurro, F, Allegrini, G, Colleoni, M, Tamberi, S, Zamagni, C, Cazzaniga, M, Orditura, M, Guarneri, V, Castelletti, D, Benelli, M, Di Marino, M, Arpino, G, De Laurentiis, M, Malorni L., Bianchini G., Caputo R., Zambelli A., Puglisi F., Bianchi G. V., Del Mastro L., Paris I., Montemurro F., Allegrini G., Colleoni M., Tamberi S., Zamagni C., Cazzaniga M. E., Orditura M., Guarneri V., Castelletti D., Benelli M., Di Marino M., Arpino G., De Laurentiis M., Malorni, L, Bianchini, G, Caputo, R, Zambelli, A, Puglisi, F, Bianchi, G, Del Mastro, L, Paris, I, Montemurro, F, Allegrini, G, Colleoni, M, Tamberi, S, Zamagni, C, Cazzaniga, M, Orditura, M, Guarneri, V, Castelletti, D, Benelli, M, Di Marino, M, Arpino, G, De Laurentiis, M, Malorni L., Bianchini G., Caputo R., Zambelli A., Puglisi F., Bianchi G. V., Del Mastro L., Paris I., Montemurro F., Allegrini G., Colleoni M., Tamberi S., Zamagni C., Cazzaniga M. E., Orditura M., Guarneri V., Castelletti D., Benelli M., Di Marino M., Arpino G., and De Laurentiis M.

Abstract

Background: Thymidine kinase 1 (TK1) is an enzyme downstream of the CDK4/6 pathway, with a critical role in DNA synthesis; serum TK1 activity (sTKa) is a novel liquid biopsy biomarker of tumour cell proliferation. Methods: The phase IIIb, BioItaLEE trial (NCT03439046) collected sera from post-menopausal patients with hormone receptor-positive (HR+), HER2-negative (HER2-) ad-vanced breast cancer (ABC) treated with first-line ribociclib plus letrozole at baseline, day 15 of cycle 1 (C1D15), day 1 of cycle 2 (C2D1), and at first imaging. Associations between sTKa assessed at different time points or sTKa dynamic patterns, and progression-free survival (PFS) were evaluated using multivariate Cox models. Results: Overall, 287 patients were enroled. Median follow-up was 26.9 months. High sTKa (> median) at baseline was associated with higher risk of progression (hazard ratio [HR], 2.21; 95% confidence interval [95% CI], 1.45, 3.37; P = 0.0002); similar results were observed for patients with high sTKa levels at C1D15 and C2D1. Early sTKa dynamic patterns were strongly predictive of PFS. The pattern with high sTKa levels at C2D1 following initial de-crease at C1D15 was associated with higher risk of progression versus the pattern with low sTKa levels at both time points (HR, 2.89; 95% CI, 1.57, 5.31; P = 0.0006), while the pattern with high sTKa levels at C1D15 was associated with the shortest PFS (HR, 5.65; CI: 2.84, 11.2; P < 0.0001). Baseline and dynamic sTKa changes provided independent information. Conclusions: sTKa appears to be a new promising prognostic and pharmacodynamic bio-marker in patients with HR+/HER2- ABC treated with ribociclib plus letrozole as first-line therapy. (c) 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Published
2023

19. Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev. 114 (2023) 102511]

Author

Miglietta, F., primary, Fabi, A., additional, Generali, D., additional, Dieci, M.V., additional, Arpino, G., additional, Bianchini, G., additional, Cinieri, S., additional, Conte, P.F., additional, Curigliano, G., additional, De Laurentiis, M., additional, Del Mastro, L., additional, De Placido, S., additional, Gennari, A., additional, Puglisi, F., additional, Zambelli, A., additional, Perrone, F., additional, and Guarneri, V., additional

Published
2023
Full Text
View/download PDF

21. Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies

Author

Russo, A, Incorvaia, L, Capoluongo, E, Tagliaferri, P, Gori, S, Cortesi, L, Genuardi, M, Turchetti, D, De Giorgi, U, Di Maio, M, Barberis, M, Dessena, M, Del Re, M, Lapini, A, Luchini, C, Jereczek-Fossa, B, Sapino, A, Cinieri, S, Beretta, G, Bella, M, Bracarda, S, Colombo, N, Conteduca, V, Del Mastro, L, Galvano, A, Gristina, V, Guarneri, V, La Verde, N, Lorusso, D, Marchetti, P, Normanno, N, Ottini, L, Pensabene, M, Pignata, S, Procopio, G, Ricevuto, E, Silvestris, N, Tassone, P, Tucci, M, Donato, V, Carrara, S, Paiella, S, Gentilini, O, Gunelli, R, Nicolis, F, Buttitta, F, Colecchia, M, Fassan, M, Malapelle, U, Marchetti, A, Marchio, C, Scarpa, A, Truini, M, Zamboni, G, Gion, M, Trevisiol, C, Gronchi, A, Danesi, R, Di Marco, V, Carrera, P, Ghiorzo, P, Pasini, B, Varesco, L, Artibani, W, Ludovico, G, Campanella, O, Vatrano, S, Tagliafico, E, Russo A., Incorvaia L., Capoluongo E., Tagliaferri P., Gori S., Cortesi L., Genuardi M., Turchetti D., De Giorgi U., Di Maio M., Barberis M., Dessena M., Del Re M., Lapini A., Luchini C., Jereczek-Fossa B. A., Sapino A., Cinieri S., Beretta G., Bella M. A., Bracarda S., Colombo N., Conteduca V., Del Mastro L., Galvano A., Gristina V., Guarneri V., La Verde N., Lorusso D., Marchetti P., Normanno N., Ottini L., Pensabene M., Pignata S., Procopio G., Ricevuto E., Silvestris N., Tassone P., Tucci M., Donato V., Carrara S., Paiella S., Gentilini O., Gunelli R., Nicolis F., Buttitta F., Colecchia M., Fassan M., Malapelle U., Marchetti A., Marchio C., Scarpa A., Truini M., Zamboni G., Gion M., Trevisiol C., Gronchi A., Danesi R., Di Marco V., Carrera P., Ghiorzo P., Pasini B., Varesco L., Artibani W., Ludovico G., Campanella O., Vatrano S., Tagliafico E., Russo, A, Incorvaia, L, Capoluongo, E, Tagliaferri, P, Gori, S, Cortesi, L, Genuardi, M, Turchetti, D, De Giorgi, U, Di Maio, M, Barberis, M, Dessena, M, Del Re, M, Lapini, A, Luchini, C, Jereczek-Fossa, B, Sapino, A, Cinieri, S, Beretta, G, Bella, M, Bracarda, S, Colombo, N, Conteduca, V, Del Mastro, L, Galvano, A, Gristina, V, Guarneri, V, La Verde, N, Lorusso, D, Marchetti, P, Normanno, N, Ottini, L, Pensabene, M, Pignata, S, Procopio, G, Ricevuto, E, Silvestris, N, Tassone, P, Tucci, M, Donato, V, Carrara, S, Paiella, S, Gentilini, O, Gunelli, R, Nicolis, F, Buttitta, F, Colecchia, M, Fassan, M, Malapelle, U, Marchetti, A, Marchio, C, Scarpa, A, Truini, M, Zamboni, G, Gion, M, Trevisiol, C, Gronchi, A, Danesi, R, Di Marco, V, Carrera, P, Ghiorzo, P, Pasini, B, Varesco, L, Artibani, W, Ludovico, G, Campanella, O, Vatrano, S, Tagliafico, E, Russo A., Incorvaia L., Capoluongo E., Tagliaferri P., Gori S., Cortesi L., Genuardi M., Turchetti D., De Giorgi U., Di Maio M., Barberis M., Dessena M., Del Re M., Lapini A., Luchini C., Jereczek-Fossa B. A., Sapino A., Cinieri S., Beretta G., Bella M. A., Bracarda S., Colombo N., Conteduca V., Del Mastro L., Galvano A., Gristina V., Guarneri V., La Verde N., Lorusso D., Marchetti P., Normanno N., Ottini L., Pensabene M., Pignata S., Procopio G., Ricevuto E., Silvestris N., Tassone P., Tucci M., Donato V., Carrara S., Paiella S., Gentilini O., Gunelli R., Nicolis F., Buttitta F., Colecchia M., Fassan M., Malapelle U., Marchetti A., Marchio C., Scarpa A., Truini M., Zamboni G., Gion M., Trevisiol C., Gronchi A., Danesi R., Di Marco V., Carrera P., Ghiorzo P., Pasini B., Varesco L., Artibani W., Ludovico G., Campanella O., Vatrano S., and Tagliafico E.

Abstract

Constitutional BRCA1/BRCA2 pathogenic or likely pathogenic variants (PVs) are associated with an increased risk for developing breast and ovarian cancers. Current evidence indicates that BRCA1/2 PVs are also associated with pancreatic cancer, and that BRCA2 PVs are associated with prostate cancer risk. The identification of carriers of constitutional PVs in the BRCA1/2 genes allows the implementation of individual and family prevention pathways, through validated screening programs and risk-reducing strategies. According to the relevant and increasing therapeutic predictive implications, the inclusion of BRCA testing in the routine management of patients with breast, ovarian, pancreatic and prostate cancers represent a key requirement to optimize medical or surgical therapeutic and prevention decision-making, and access to specific anticancer therapies. Therefore, accurate patient selection, the use of standardized and harmonized procedures, and adherence to homogeneous testing criteria, are essential elements to implement BRCA testing in clinical practice. This consensus position paper has been developed and approved by a multidisciplinary Expert Panel of 64 professionals on behalf of the AIOM–AIRO–AISP–ANISC–AURO–Fondazione AIOM–SIAPEC/IAP–SIBioC–SICO–SIF–SIGE–SIGU–SIU–SIURO–UROP Italian Scientific Societies, and a patient association (aBRCAdaBRA Onlus). The working group included medical, surgical and radiation oncologists, medical and molecular geneticists, clinical molecular biologists, surgical and molecular pathologists, organ specialists such as gynecologists, gastroenterologists and urologists, and pharmacologists. The manuscript is based on the expert consensus and reports the best available evidence, according to the current eligibility criteria for BRCA testing and counseling, it also harmonizes with current Italian National Guidelines and Clinical Recommendations.

Published
2022

22. 101P Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: An individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies

Author

Lambertini, M., primary, Blondeaux, E., additional, Bisagni, G., additional, Mura, S., additional, de Placido, S., additional, De Laurentiis, M., additional, Fabi, A., additional, Rimanti, A., additional, Michelotti, A., additional, Mansutti, M., additional, Russo, A., additional, Montemurro, F., additional, Frassoldati, A., additional, Durando, A., additional, Gori, S., additional, Turletti, A., additional, Tamberi, S., additional, Urracci, Y., additional, de Azambuja, E., additional, and Del Mastro, L., additional

Published
2023
Full Text
View/download PDF

23. 35P SNPs of aromatase gene (CYP19A1) and outcomes of patients with estrogen receptor-positive (ER+) early breast cancer (eBC) treated with aromatase inhibitors (AIs): A multicenter, prospective study

Author

Conte, B., primary, Boni, L., additional, Bisagni, G., additional, Durando, A., additional, Sanna, G., additional, Gori, S., additional, Garrone, O., additional, Tamberi, S., additional, de Placido, S., additional, Schettini, F., additional, Pazzola, A., additional, Ponzone, R., additional, Montemurro, F., additional, Lunardi, G., additional, Piccioli, P., additional, Turletti, A., additional, Bighin, C., additional, Poggio, F., additional, Lambertini, M., additional, and Del Mastro, L., additional

Published
2023
Full Text
View/download PDF

24. 199P Correlation of circulating tumor DNA (ctDNA) or thymidine kinase activity (TKa) dynamic patterns with tumor response in patients (pts) with hormone receptor (HR)+ human epidermal growth factor 2 (HER2)– advanced breast cancer (ABC) on ribociclib (RIB) + letrozole (LET) in BioItaLEE trial

Author

Arpino, G., primary, Bianchini, G., additional, Malorni, L., additional, Caputo, R., additional, Zambelli, A., additional, Puglisi, F., additional, Del Mastro, L., additional, Colleoni, M.A., additional, Montemurro, F., additional, Bianchi, G.V., additional, Paris, I., additional, Allegrini, G., additional, Tamberi, S., additional, Cazzaniga, M.E., additional, Orditura, M., additional, Zamagni, C., additional, Suter, M.B., additional, Fenderico, N., additional, and De Laurentiis, M., additional

Published
2023
Full Text
View/download PDF

25. 276P Safety of pregnancy after early breast cancer in young women with hormone receptor-positive disease: A systematic review and meta-analysis

Author

Arecco, L., primary, Blondeaux, E., additional, Bruzzone, M., additional, Latocca, M.M., additional, Mariamidze, E., additional, Begijanashvili, S., additional, Sokolovic, E., additional, Scavone, G., additional, Ottonello, S., additional, Boutros, A., additional, Luis, I.V. Vaz, additional, Manich, C. Saura, additional, Anderson, R.A., additional, Demeestere, I., additional, Azim, H.A., additional, de Azambuja, E., additional, Peccatori, F.A., additional, Del Mastro, L., additional, Partridge, A.H., additional, and Lambertini, M., additional

Published
2023
Full Text
View/download PDF

26. 83P Exoxomes and miRNA in breast cancer cancerogenesis: A case-control study

Author

Cardinali, B., primary, Piccioli, P., additional, Zinoli, L., additional, Coco, S., additional, Sciutto, A., additional, Bruzzo, C., additional, Cavalieri, Z., additional, Chiorino, G., additional, Ostano, P., additional, Tasso, R., additional, Quarto, R., additional, Ceresa, D., additional, Malatesta, P., additional, Rubagotti, A., additional, Boccardo, F., additional, and Del Mastro, L., additional

Published
2023
Full Text
View/download PDF

27. 209P Trastuzumab plus lapatinib or chemotherapy in patients with HER2-positive advanced breast cancer refractory to anti-HER2 therapies: A randomized, multicenter, phase II trial (GIM12-TYPHER)

Author

De Angelis, C., primary, Pagliuca, M., additional, Gamucci, T., additional, Mansutti, M., additional, Ballatore, Z., additional, De Laurentiis, M., additional, Bordonaro, R., additional, Pazzola, A., additional, Leonardi, V., additional, Bruzzese, D., additional, Mosconi, A.M., additional, Molica, C., additional, Cinieri, S., additional, Fabi, A., additional, Del Mastro, L., additional, Puglisi, F., additional, de Placido, S., additional, Giuliano, M., additional, and Arpino, G., additional

Published
2023
Full Text
View/download PDF

28. 108P Safety results of post-neoadjuvant T-DM1 in the Italian compassionate use program (GIM26-TRASTHER study)

Author

Poggio, F., primary, Tagliamento, M., additional, Favero, D., additional, De Laurentiis, M., additional, Tonini, G., additional, Bernardo, A., additional, Ferraris, E., additional, Paris, I., additional, Riccardi, F., additional, Bianchi, G.V., additional, Cancello, G., additional, Chini, C., additional, Fontana, A., additional, Bisagni, G., additional, Crippa, A., additional, Gennari, A., additional, Berardi, R., additional, Musolino, A., additional, Lambertini, M., additional, and Del Mastro, L., additional

Published
2023
Full Text
View/download PDF

29. 66P Outcome predictors for pembrolizumab alone or with chemotherapy in advanced non-small cell lung cancer (NSCLC)

Author

Zullo, L., primary, Cella, E., additional, Paoloni, F., additional, Gualtieri, M., additional, Barletta, G., additional, Favero, D., additional, Parisi, F., additional, Dellepiane, C., additional, Rossi, G., additional, Bennicelli, E., additional, Zinoli, L., additional, Cantini, L., additional, Pecci, F., additional, Del Mastro, L., additional, Berardi, R., additional, and Genova, C., additional

Published
2023
Full Text
View/download PDF

30. P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes

Author

Johnston, S., primary, Toi, M., additional, O’Shaughnessy, J., additional, Rastogi, P., additional, Campone, M., additional, Neven, P., additional, Huang, C.S., additional, Huober, J., additional, Jaliffe, G. Garnica, additional, Cicin, I., additional, Tolaney, S., additional, Goetz, M.P., additional, Rugo, H., additional, Senkus, E., additional, Testa, L., additional, Del Mastro, L., additional, Shimizu, C., additional, Wei, R., additional, Shahir, A., additional, Munoz, M., additional, Antonio, B. San, additional, Andre, V., additional, Harbeck, N., additional, and Martín, M., additional

Published
2023
Full Text
View/download PDF

31. Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review

Author

Miglietta, F., primary, Fabi, A., additional, Generali, D., additional, Dieci, M.V., additional, Arpino, G., additional, Bianchini, G., additional, Cinieri, S., additional, Conte, P.F., additional, Curigliano, G., additional, De Laurentiis, M., additional, Del Mastro, L., additional, De Placido, S., additional, Gennari, A., additional, Puglisi, F., additional, Zambelli, A., additional, Perrone, F., additional, and Guarneri, V., additional

Published
2023
Full Text
View/download PDF

32. Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis.

Author

Arecco, Luca, Blondeaux, Eva, Bruzzone, Marco, Latocca, Maria Maddalena, Mariamidze, Elene, Begijanashvili, Salome, Sokolovic, Emir, Gentile, Giulia, Scavone, Graziana, Ottonello, Silvia, Boutros, Andrea, Vaz-Luis, Ines, Saura, Cristina, Anderson, R A, Demeestere, Isabelle, Azim, H A, de Azambuja, Evandro, Peccatori, Fedro Alessandro, Del Mastro, L, Partridge, Ann H, Lambertini, Matteo Md Phd M., Arecco, Luca, Blondeaux, Eva, Bruzzone, Marco, Latocca, Maria Maddalena, Mariamidze, Elene, Begijanashvili, Salome, Sokolovic, Emir, Gentile, Giulia, Scavone, Graziana, Ottonello, Silvia, Boutros, Andrea, Vaz-Luis, Ines, Saura, Cristina, Anderson, R A, Demeestere, Isabelle, Azim, H A, de Azambuja, Evandro, Peccatori, Fedro Alessandro, Del Mastro, L, Partridge, Ann H, and Lambertini, Matteo Md Phd M.

Abstract

Despite increasing evidence on the safety of pregnancy after anticancer treatments in breast cancer survivors, many physicians and patients remain concerned about a potential risk of pregnancy specifically in the case of hormone receptor-positive breast cancer., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2023

33. Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group

Author

Gampenrieder, S.P., primary, Dezentjé, V., additional, Lambertini, M., additional, de Nonneville, A., additional, Marhold, M., additional, Le Du, F., additional, Cortés Salgado, A., additional, Alpuim Costa, D., additional, Vaz Batista, M., additional, Chic Ruché, N., additional, Tinchon, C., additional, Petzer, A., additional, Blondeaux, E., additional, Del Mastro, L., additional, Targato, G., additional, Bertucci, F., additional, Gonçalves, A., additional, Viret, F., additional, Bartsch, R., additional, Mannsbart, C., additional, Deleuze, A., additional, Robert, L., additional, Saavedra Serrano, C., additional, Gion Cortés, M., additional, Sampaio-Alves, M., additional, Vitorino, M., additional, Pecen, L., additional, Singer, C., additional, Harbeck, N., additional, Rinnerthaler, G., additional, Greil, R., additional, Balic, Marija, additional, Heibl, Sonja, additional, Zabernigg, August Felix, additional, Egle, Daniel, additional, Sandholzer, Margit, additional, Roitner, Florian, additional, Andel, Johannes, additional, Pichler, Petra, additional, Hager, Christopher, additional, Knauer, Michael, additional, Hubalek, Michael, additional, Bighin, Claudia, additional, De Laurentiis, Michelino, additional, De Placido, Sabino, additional, Puglisi, Fabio, additional, Boni, Luca, additional, de Gregorio, Amelie, additional, Degenhardt, Tom, additional, Formisano, Luigi, additional, Beelen, Karin, additional, Robinson, Timothy, additional, Fitzpatrick, Amanda, additional, Dieras, Veronique, additional, Muller, Volkmar, additional, Gennari, Alessandra, additional, Linn, Sabine, additional, Braga, Sofia, additional, Cortes, Javier, additional, and Palmieri, Carlo, additional

Published
2023
Full Text
View/download PDF

36. 270P Defining clinico-pathological characteristics of HER2 positive metastatic breast cancer (MBC) patients experiencing radiologic complete response (rCR) in a nationwide real-world cohort

Author

Cucciniello, L., primary, Blondeaux, E., additional, Bighin, C., additional, Gasparro, M.S., additional, Russo, S., additional, Dri, A., additional, Pugliese, P., additional, Fontana, A., additional, Naso, G., additional, Ferzi, A., additional, Riccardi, F., additional, Sini, V., additional, Fabi, A., additional, Montemurro, F., additional, De Laurentiis, M., additional, Arpino, G., additional, Del Mastro, L., additional, Gerratana, L., additional, and Puglisi, F., additional

Published
2022
Full Text
View/download PDF

37. 134O Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)

Author

Del Mastro, L., primary, Poggio, F., additional, Blondeaux, E., additional, de Placido, S., additional, Giuliano, M., additional, De Laurentiis, M., additional, Bisagni, G., additional, Cantore, M., additional, Turletti, A., additional, Nisticò, C., additional, Urracci, Y., additional, Garrone, O., additional, Bighin, C., additional, Mansutti, M., additional, Montemurro, F., additional, Colantuoni, G., additional, Lambertini, M., additional, and Boni, L., additional

Published
2022
Full Text
View/download PDF

39. 1099P Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients

Author

Parisi, F., primary, De Luca, G., additional, Rossi, G., additional, Coco, S., additional, Dellepiane, C., additional, Bennicelli, E., additional, Zinoli, L., additional, Zullo, L., additional, Alama, A., additional, Mosconi, M., additional, Mora, M., additional, Ballestrero, A., additional, Montecucco, F., additional, Marconi, S., additional, Pronzato, P., additional, Del Mastro, L., additional, Nozza, P., additional, Bellodi, A., additional, Dono, M., additional, and Genova, C., additional

Published
2022
Full Text
View/download PDF

41. 357P Bridging the gap between real-world studies (RWSs) and randomized controlled trials (RCTs) of 1st-line palbociclib+aromatase inhibitors (P+AI) in hormone receptor-positive (HR+)/HER2-negative(-) metastatic breast cancer (mBC)

Author

Nucera, S., Schettini, F., Giudici, F., Strina, C., Milani, M., Tancredi, R.J., Conte, B., Criscitiello, C., Giuliano, M., Lambertini, M., Bayona, R. Sanchez, Pascual, T., Vigneri, P., Arpino, G., Del Mastro, L., Cristofanilli, M., Rugo, H.S., Gennari, A., Curigliano, G., and Generali, D.

Published
2024
Full Text
View/download PDF

42. 243P Prognosis of patients with hormone receptor-positive/HER2-negative early breast cancer according to monarchE and NATALEE trials risk categories: Patient-level analysis of Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) randomised trials

Author

Arecco, L., Blondeaux, E., Bruzzone, M., Arpino, G., De Angelis, C., De Laurentiis, M., Caputo, R., Fabi, A., V. sanna, Gori, S., Puglisi, F., Boni, L., Nardin, S., Giannubilo, I., Perachino, M., Borea, R., Agostinetto, E., de Azambuja, E., Lambertini, M., and Del Mastro, L.

Published
2024
Full Text
View/download PDF

46. P-463 Anti-Müllerian hormone levels in breast cancer patients receiving chemotherapy with or without concurrent luteinizing hormone-releasing hormone agonist: results from the PROMISE phase III trial

Author

Marrocco, C, primary, Conte, B, additional, Rossi, G, additional, Pirrone, C, additional, Favero, D, additional, Massarotti, C, additional, Anserini, P, additional, Fregatti, P, additional, Cardinali, B, additional, Buzzati, G, additional, Levaggi, A, additional, Poggio, F, additional, Blondeaux, E, additional, Del Mastro, L, additional, and Lambertini, M, additional

Published
2022
Full Text
View/download PDF

47. Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

Author

Cazzaniga, M, Verusio, C, Ciccarese, M, Fumagalli, A, Sartori, D, Valerio, M, Airoldi, M, Moretti, G, Ficorella, C, Gianni, L, Michelotti, A, Zambelli, A, Febbraro, A, Generali, D, Pistelli, M, Garrone, O, Musolino, A, Vici, P, Maur, M, Mentuccia, L, La Verde, N, Bianchi, G, Artale, S, Blasi, L, De Laurentiis, M, Atzori, F, Turletti, A, Porpiglia, M, Santini, D, Fabi, A, Gebbia, V, Schirone, A, Palumbo, R, Ferzi, A, Frassoldati, A, Scavelli, C, Clivio, L, Giordano, M, Donadio, M, Biganzoli, L, Del Mastro, L, Bisagni, G, Livi, L, Natoli, C, Montemurro, F, Riccardi, F, Romagnoli, E, Marchetti, P, Torri, V, Pronzato, P, Mustacchi, G, Cazzaniga M. E., Verusio C., Ciccarese M., Fumagalli A., Sartori D., Valerio M. R., Airoldi M., Moretti G., Ficorella C., Gianni L., Michelotti A., Zambelli A., Febbraro A., Generali D., Pistelli M., Garrone O., Musolino A., Vici P., Maur M., Mentuccia L., La Verde N., Bianchi G. V., Artale S., Blasi L., De Laurentiis M., Atzori F., Turletti A., Porpiglia M., Santini D., Fabi A., Gebbia V., Schirone A., Palumbo R., Ferzi A., Frassoldati A., Scavelli C., Clivio L., Giordano M., Donadio M., Biganzoli L., Del Mastro L., Bisagni G., Livi L., Natoli C., Montemurro F., Riccardi F., Romagnoli E., Marchetti P., Torri V., Pronzato P., Mustacchi G., Cazzaniga, M, Verusio, C, Ciccarese, M, Fumagalli, A, Sartori, D, Valerio, M, Airoldi, M, Moretti, G, Ficorella, C, Gianni, L, Michelotti, A, Zambelli, A, Febbraro, A, Generali, D, Pistelli, M, Garrone, O, Musolino, A, Vici, P, Maur, M, Mentuccia, L, La Verde, N, Bianchi, G, Artale, S, Blasi, L, De Laurentiis, M, Atzori, F, Turletti, A, Porpiglia, M, Santini, D, Fabi, A, Gebbia, V, Schirone, A, Palumbo, R, Ferzi, A, Frassoldati, A, Scavelli, C, Clivio, L, Giordano, M, Donadio, M, Biganzoli, L, Del Mastro, L, Bisagni, G, Livi, L, Natoli, C, Montemurro, F, Riccardi, F, Romagnoli, E, Marchetti, P, Torri, V, Pronzato, P, Mustacchi, G, Cazzaniga M. E., Verusio C., Ciccarese M., Fumagalli A., Sartori D., Valerio M. R., Airoldi M., Moretti G., Ficorella C., Gianni L., Michelotti A., Zambelli A., Febbraro A., Generali D., Pistelli M., Garrone O., Musolino A., Vici P., Maur M., Mentuccia L., La Verde N., Bianchi G. V., Artale S., Blasi L., De Laurentiis M., Atzori F., Turletti A., Porpiglia M., Santini D., Fabi A., Gebbia V., Schirone A., Palumbo R., Ferzi A., Frassoldati A., Scavelli C., Clivio L., Giordano M., Donadio M., Biganzoli L., Del Mastro L., Bisagni G., Livi L., Natoli C., Montemurro F., Riccardi F., Romagnoli E., Marchetti P., Torri V., Pronzato P., and Mustacchi G.

Abstract

Background: Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting. Methods: For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). Results: Eighty-one and 91 patients have been identified from the two data sets. The median age was 63 years (range 35-82) for the EVA and 57.8 years (range 35.0-82.3) for the AMBRA patients. ORRs were 23.5 and 24.3% in the whole population, 26.9% in the patients with bone only, and 21.8 and 21.4% in those with visceral metastases. The median duration of HD-FUL was 11.6 months (range 1-48) and 12.4 months (range 2.9-70.0) in the two data sets, respectively. Conclusion: These data suggest that HD-FUL should still continue to play a significant role as first-line therapy in HR+ ABC patients.

Published
2020

48. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

Author

Schettini, F., Venturini, Sergio, Giuliano, M., Lambertini, M., Pinato, D. J., Onesti, C. E., De Placido, P., Harbeck, N., Luftner, D., Denys, H., Van Dam, P., Arpino, G., Zaman, K., Mustacchi, G., Gligorov, J., Awada, A., Campone, M., Wildiers, H., Gennari, Alessandro, Tjan-Heijnen, V., Bartsch, R., Cortes, J., Paris, Ida, Martin, M., De Placido, S., Del Mastro, L., Jerusalem, G., Curigliano, G., Prat, A., Generali, Daniele, Venturini S. (ORCID:0000-0002-6574-3337), Gennari A., Paris I., Generali D. (ORCID:0000-0003-2480-3855), Schettini, F., Venturini, Sergio, Giuliano, M., Lambertini, M., Pinato, D. J., Onesti, C. E., De Placido, P., Harbeck, N., Luftner, D., Denys, H., Van Dam, P., Arpino, G., Zaman, K., Mustacchi, G., Gligorov, J., Awada, A., Campone, M., Wildiers, H., Gennari, Alessandro, Tjan-Heijnen, V., Bartsch, R., Cortes, J., Paris, Ida, Martin, M., De Placido, S., Del Mastro, L., Jerusalem, G., Curigliano, G., Prat, A., Generali, Daniele, Venturini S. (ORCID:0000-0002-6574-3337), Gennari A., Paris I., and Generali D. (ORCID:0000-0003-2480-3855)

Abstract

Metastatic triple-negative breast cancer (mTNBC) is a poor prognostic disease with limited treatments and un-certain therapeutic algorithms. We performed a systematic review and multiple Bayesian network meta-analyses according to treatment line to establish an optimal therapeutic sequencing strategy for this lethal disease. We included 125 first-line trials (37,812 patients) and 33 s/further-lines trials (11,321 patients). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rates (ORR), overall survival (OS) and safety, for first and further lines, separately. We also estimated separate treatment rankings for the first and subsequent lines according to each endpoint, based on (surface under the cumulative ranking curve) SUCRA values. No first-line treatment was associated with superior PFS and OS than paclitaxel +/- bevacizumab. Platinum-based polychemotherapies were generally superior in terms of ORR, at the cost of higher toxicity.. PARP-inhibitors in germline-BRCA1/2-mutant patients, and immunotherapy + chemotherapy in PD-L1 -positive mTNBC, performed similar to paclitaxel +/- bevacizumab. In PD-L1-positive mTNBC, pembrolizumab + chemotherapy was better than atezolizumab + nab-paclitaxel in terms of OS according to SUCRA values. In second/further-lines, sacituzumab govitecan outperformed all other treatments on all endpoints, followed by PARP-inhibitors in germline-BRCA1/2-mutant tumors. Trastuzumab deruxtecan in HER2-low mTNBC performed similarly and was the best advanced-line treatment in terms of PFS and OS after sacituzumab govitecan, ac-cording to SUCRA values. Moreover, comparisons with sacituzumab govitecan, talazoparib and olaparib were not statistically significant. The most effective alternatives or candidates for subsequent lines were represented by nab-paclitaxel (in ORR), capecitabine (in PFS) and eribulin (in PFS and OS).

Published
2022

50. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

Author

Gianni, L., primary, Huang, C.S., additional, Egle, D., additional, Bermejo, B., additional, Zamagni, C., additional, Thill, M., additional, Anton, A., additional, Zambelli, S., additional, Bianchini, G., additional, Russo, S., additional, Ciruelos, E.M., additional, Greil, R., additional, Semiglazov, V., additional, Colleoni, M., additional, Kelly, C., additional, Mariani, G., additional, Del Mastro, L., additional, Maffeis, I., additional, Valagussa, P., additional, and Viale, G., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results